{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T08:40:05Z","timestamp":1747903205854,"version":"3.41.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-025-04126-4","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T08:03:32Z","timestamp":1747901012000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of three loading doses of bevacizumab and ranibizumab for macular edema due to branch retinal vein occlusion"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5752-9090","authenticated-orcid":false,"given":"Sibel Co\u015fkun","family":"Akdemir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurdan Gamze","family":"Ta\u015fl\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"4126_CR1","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1097\/IAE.0b013e3182870c15","volume":"33","author":"A -Jaulim","year":"2013","unstructured":"Jaulim A, Ahmed B, Khanam T, Chatziralli IP. Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina. 2013;33:901\u201310.","journal-title":"Retina"},{"key":"4126_CR2","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00417-004-1087-4","volume":"244","author":"H -Noma","year":"2006","unstructured":"Noma H, Minamoto A, Funatsu H, Tsukamoto H, Nakano K, Yamashita H, Mishima HK. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2006;244:309\u201315.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"4126_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000502041","volume":"242","author":"U -Schmidt-Erfurth","year":"2019","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Gerendas, Bianca, et al. Guidelines for the management of retinal vein occlusion by the European society of retina specialists (Euretina). Ophthalmologica. 2019;242(3):123\u201362.","journal-title":"Ophthalmologica"},{"issue":"7","key":"4126_CR4","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/bjophthalmol-2014-306543","volume":"99","author":"R -Narayanan","year":"2015","unstructured":"Narayanan R, Panchal B, Das T, Chhablani J, Jalali S, Ali MH, MARVEL study group. A randomised, double- masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL report 1. Br J Ophthalmol. 2015;99(7):954\u20139.","journal-title":"Br J Ophthalmol"},{"key":"4126_CR5","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","volume":"117","author":"PA -Compochiaro","year":"2010","unstructured":"Compochiaro PA, Heier JS, FeinerbL, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG. Invest,gators B: ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase 3 study. Ophthalmology. 2010;117:1102\u201312.","journal-title":"Ophthalmology"},{"key":"4126_CR6","first-page":"105108","volume":"11","author":"M -Annie","year":"2018","unstructured":"Annie M, WU, Comnie M, et al. The use of bevacizumab and ranibizumab for branch retinal vein occlusion in medicare beneficiaries. Am J Ophthalmol Case Rep. 2018;11:105108.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"6","key":"4126_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3928\/23258160-20170601-04","volume":"48","author":"M -Khan","year":"2017","unstructured":"Khan M, Wa\u015f KM, Silva FQ, et al. Comparison of ranibizumab and bevacizumab for macular edema secondary tomretinal vein occlusions in routine clinical practice. Ophthalmic Surg Lasers Imaging Retina. 2017;48(6):465\u201372.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"4126_CR8","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/IAE.0000000000001224","volume":"37","author":"Y -Miwa","year":"2017","unstructured":"Miwa Y, Muraoka Y, Osaka R, et al. Ranibizumab for macular edema after branch retinal vein occlusion: one initial injection versus three monthly injections. Retina. 2017;37:702\u20139.","journal-title":"Retina"},{"key":"4126_CR9","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s40123-022-00588-7","volume":"11","author":"T -Wenyi","year":"2022","unstructured":"Wenyi T, Jingli G, et al. Three monthly injections versus one initial injection of ranibizumab for the treatment of macular edema secondary to branch retinal vein occlusion: 12- month results of a prospective randomized study. Ophthalmol Therapy. 2022;11:2309\u201320.","journal-title":"Ophthalmol Therapy"},{"issue":"3","key":"4126_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3341\/kjo.2015.0158","volume":"31","author":"BK -Son","year":"2017","unstructured":"Son BK, Kwak HW, Kim ES, et al. Comparison of ranibizumab and bevacizumab for macular edema associated with branch retinal vein occlusion. Korean J Ophthalmol. 2017;31(3):209\u201316.","journal-title":"Korean J Ophthalmol"},{"issue":"6","key":"4126_CR11","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.oret.2019.12.019","volume":"4","author":"MJC -Vader","year":"2020","unstructured":"Vader MJC, Schauwvlieghe ME, et al. Comparing the efficacy of bevacizumab and ranibizumab in patients with retinal vein occlusion: the bevacizumab to ranibizumab in retinal vein occlusions (BRVO) study, a randomized trial. Ophthalmol Retina. 2020;4(6):576\u201387.","journal-title":"Ophthalmol Retina"},{"key":"4126_CR12","first-page":"692","volume":"387","author":"DJ -Chirag","year":"2022","unstructured":"Chirag DJ, et al. Aflibercept monotherapy or bevacizumab first for diabetic macular edema. N Eng J Med. 2022;387:692\u2013703.","journal-title":"J Med"},{"key":"4126_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2147\/OPTH.S76261","volume":"9","author":"Y -Ito","year":"2015","unstructured":"Ito Y, Saishin Y, Sawada O, et al. Comparison of single injection and three monthly injections of intravitreal bevacizumab for macular edema associated with branch retinal vein occlusion. Clin Ophthalmol. 2015;9:175\u201380.","journal-title":"Clin Ophthalmol"},{"key":"4126_CR14","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/mt.2008.10","volume":"16","author":"PA -Campochiaro","year":"2008","unstructured":"Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of vegf as a critical stimulator. Mol Therapy: J Am Soc Gene Therapy. 2008;16:791\u20139.","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"key":"4126_CR15","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","volume":"114","author":"SJ -Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intrvitreal bevacizumab (Avastin). Ophthalmology. 2007;114:855\u20139.","journal-title":"Ophthalmology"},{"issue":"4","key":"4126_CR16","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","volume":"146","author":"TU -Krohne","year":"2008","unstructured":"Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humana. Am J Ophthalmol. 2008;146(4):508\u201312.","journal-title":"Am J Ophthalmol"},{"key":"4126_CR17","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ajo.2012.03.047","volume":"154","author":"TU -Krohne","year":"2012","unstructured":"Krohne TU, Liu Z, Holz FG, Meyer CH. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012;154:682\u20136.","journal-title":"Am J Ophthalmol"},{"key":"4126_CR18","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1167\/iovs.12-10260","volume":"54","author":"L -Xu","year":"2013","unstructured":"Xu L, Lu T, Tuomi L, et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci. 2013;54:1616\u201324.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"4126_CR19","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","volume":"37","author":"RL -Avery","year":"2017","unstructured":"Avery RL, Castellarin, Alessandro A, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 2017;37(10):1847\u201358.","journal-title":"Retina"},{"issue":"12","key":"4126_CR20","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.3346\/jkms.2012.27.12.1580","volume":"27","author":"DJ -Hwang","year":"2012","unstructured":"Hwang DJ, Kim YE, et al. Comparison of systemic adverse events associated with intravitreal anti- VEGF injection: ranibizumab versus bevacizumab. J Korean Med Sci. 2012;27(12):1580\u20135.","journal-title":"J Korean Med Sci"},{"issue":"3","key":"4126_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/IAE.0b013e31819a5f98","volume":"29","author":"I -Ladas","year":"2009","unstructured":"Ladas I, Karag\u0131anis, Dimitrios A, et al. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab. Retina. 2009;29(3):313\u20138.","journal-title":"Retina"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04126-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-025-04126-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04126-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T08:03:33Z","timestamp":1747901013000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-025-04126-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4126"],"URL":"https:\/\/doi.org\/10.1186\/s12886-025-04126-4","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"8 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants followed the ethical standards of the institutional and\/or national research committee and the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study protocol was approved by the University of Health Sciences, Trabzon Faculty of Medicine institutional clinical research ethics committee (number:2024\/49). Written informed consent was obtained from all the participants of the study,","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"304"}}